Textbook of Personalized Medicine - Second Edition [2015]

426 Biomarkers of Epilepsy With so many different types of seizures and causes of epilepsy, there are no univer- sal biomarkers ...

427 be a stress biomarker in TLE in that it correlates inversely with memory scores and hippocampal volume. In addition, the sym ...

428 testing for risk assessment and personalized treatment (Kearney 2012 ). Personalized WES is already available and WGS is lik ...

429 Choice of the Right Antiepileptic Drug The primary criterion for the selection of antiepileptic drugs (AEDs) is the patient’ ...

430 (SCN1A) and drug transport (ABCB1) proteins can infl uence the effi cacy of AEDs as shown in Table 12.5. The common SCN1A sp ...

431 Pharmacogenetics of Epilepsy More than one-third of the patients experience adverse drug reactions (ADRs) with AED treatment ...

432 Neuroinfl ammation also plays a key role of in the pathophysiology of resistant epi- lepsy. Furthermore, transporter polymor ...

433 act on the receptor is unknown. The main weakness of the target hypothesis is its presumption of a working knowledge of the ...

434 There is ample scope for penetration by new products with a benign side effect pro- fi le and/or higher effectiveness. Sever ...

435 guidelines that are based on pharmacogenetic data. Various suggestions that have been made to facilitate development of pers ...

436 ATP1A2, encoding a catalytic subunit of a sodium-potassium-ATPase, have been found in some families with dominantly inherite ...

437 different types of headaches. Most headache medications have more than one component, e.g. combination of acetylsalicylic ac ...

438 Brain Imaging in Trials of Restorative Therapies for Stroke Several restorative therapies for stroke are under investigation ...

439 a microsurgical anastomosis between the superfi cial temporal and the middle artery branches, to reroute blood in cases with ...

440 The methods selected are the considered to be most effective based on evidence available so far. Cell therapy plays an impor ...

441 The focus in treatment of multiple sclerosis is on neuroprotection, i.e. therapy that stops or slows the progression of the ...

442 patients if the T cell receptor activation pattern of each patient is determined at dif- ferent stages of the disease. The B ...

443 extremely severe courses of the disease. The high therapeutic effi cacy of this substance, which originates from oncology, i ...

444 Fusokine Method of Personalized Cell Therapy of Multiple Sclerosis Fusokine (GIFT15), a cytokine prepared by fusion of granu ...

445 analyses to determine the genetic elements controlling MS. The data from this study suggest that early initiation of treatme ...